Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;92(11):1711-1722.
doi: 10.1016/j.mayocp.2017.09.001. Epub 2017 Nov 1.

Pharmacogenomics: Precision Medicine and Drug Response

Affiliations
Review

Pharmacogenomics: Precision Medicine and Drug Response

Richard M Weinshilboum et al. Mayo Clin Proc. 2017 Nov.

Abstract

Pharmacogenomics is the use of genomic and other "omic" information to individualize drug selection and drug use to avoid adverse drug reactions and to maximize drug efficacy. The science underlying pharmacogenomics has evolved rapidly over the 50 years since it was first suggested that genetics might influence drug response phenotypes. That process has occurred in parallel with advances in DNA sequencing and other molecular technologies, with striking increases in our understanding of the human genome. There are now many validated examples of the clinical utility of pharmacogenomics, and this type of clinical genomic information is increasingly being generated in clinical laboratories, incorporated into electronic health records, and used to "tailor" or individualize drug therapy. This review will survey the origins and development of pharmacogenomics; it will address some of the challenges associated with the clinical implementation of pharmacogenomics; and it will attempt to foresee future advances in this important genomic discipline, one that almost certainly will be among the earliest and most widely adopted aspects of clinical genomics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmacogenomic Discovery, Translation, Implementation
Figure 2
Figure 2
Pharmacogenomics to Pharmaco-Omics
Figure 3
Figure 3
Pharmaco-Omics, The Future

References

    1. Weinshilboum RM, Wang L. Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation. Annual Rev Genomics Hum Genet. 2006;7:223–245. - PubMed
    1. Wang L, McLeod HL, Weinshilboum RM. Genomics and Drug Response. N Engl J Med. 2011;364:1144–1153. - PMC - PubMed
    1. Giacomini KM, Yee SW, Ratain MG, Weinshilboum RM, Kamatani N, Nakamura Y. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26;4(153) - PMC - PubMed
    1. Motulsky AG. Drug reactions enzymes and biochemical genetics. JAMA. 1957;165:835–837. - PubMed
    1. Kalow W. Familial incidence of low pseudocholinesterase level. The Lancet. 1956;2:576–577. - PubMed

Publication types

MeSH terms